REPORT ON FILE · CURRENT PRODUCT
Retatrutide 10 mg
Lot r10-feb26-yellow · Reported February 22, 2026 · Accession 2602200165
THE BODEGA RECORD SHELF
COA Library
Open the privacy-redacted report images on file. Client identifiers are hidden for privacy; lot numbers, dates, accession numbers, and analytical results remain visible. Current-product and prior-lot labels remain distinct, and a prior-lot report never establishes the identity or quality of a current lot.
REPORTS ON FILE
8 records
OPEN REPORT ↗
REPORT ON FILE · CURRENT PRODUCT
Tirzepatide 20 mg
Lot t20-mar-2026-p · Reported March 22, 2026 · Accession 2603200123
REPORT ON FILE · CURRENT PRODUCT
Tirzepatide 40 mg
Lot t40-mar26-blue · Reported March 5, 2026 · Accession 2603040037
REPORT ON FILE · CURRENT PRODUCT
CJC-1295 (no DAC) 5 mg + Ipamorelin 5 mg
10 mg total · Lot cjp10-june-26 · Reported June 18, 2026 · Accession 2606160283
PRIOR LOT REPORT · CURRENT PRODUCT AVAILABLE
Retatrutide 30 mg
Lot r30-0126-gold · Reported January 21, 2026 · Accession 2601190024
PRIOR LOT REPORT · CURRENT PRODUCT AVAILABLE
Retatrutide 30 mg
Batch r30-mar26-bee · Analyzed March 5, 2026 · Janoshik task 110730
PRIOR LOT REPORT · CURRENT PRODUCT AVAILABLE
GHK-Cu 100 mg · Content and purity
Batch March MOQ GB · Analyzed April 8, 2026 · Janoshik task 124929
PRIOR LOT REPORT · CURRENT PRODUCT AVAILABLE
GHK-Cu 100 mg · Sterility
Batch March MOQ GB · Analyzed April 8, 2026 · Janoshik task 124932
DOCUMENT RULE
Keep the report attached to the right lot.
Purity alone does not establish identity, sterility, endotoxin control, fill accuracy, or stability. Verify current-lot documentation before fulfillment.